Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Status:
Unknown status
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
Primary Outcome Measures:
Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ]
Secondary Outcome Measures:
The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The
area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-∞); The
time to reach the maximum plasma concentration after treatment (Tmax) Total clearance (CL);
Elimination of half-life (t1 / 2); Apparent distribution volume (Vd).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd